RAPID PORTABLE DETECTION OF DELAYED GASTRIC EMPTYING

该研究旨在开发一种快速诊断胃排空延迟的创新技术。新技术有望克服现有方法的局限性，包括辐射暴露、准确性、便携性、可用性和成本。基本假设是胃音与胃动力和排空模式相关。声学传感器（接触式麦克风）将采集这些声音，同时计算机分析并报告是否存在与胃排空延迟诊断一致的变化。我们预计，最终产品将既便宜又便携。这项技术可能导致与胃排空延迟相关的发病率和医疗保健费用大幅降低。第一阶段研究将通过记录正常受试者和胃排空延迟受试者的胃音模式来测试人类的可行性。如果成功，这种新型设备将具有巨大的商业潜力，可能被医院、医疗和外科团体以及为糖尿病、饮食失调和胃肠病患者服务的专科诊所购买。拟议的商业应用：本研究旨在开发一种具有潜在大市场的新型诊断设备。预计这些产品将成为医院、团体医疗实践和诊所的标准设备，为胃肠道疾病患者提供服务。该器械将特别用于随访胃排空延迟风险较高的患者，如糖尿病、饮食失调和肾衰竭患者。初步的10年销售额和利润预测分别为1.82亿美元和3400万美元。

The proposed research is to develop an innovative technology for the rapid diagnosis of delayed gastric emptying. The new technology is expected to overcome limitations of the current methods which may include radiation exposure, accuracy, portability, availability and cost. The essential hypothesis is that gastric sounds correlate with gastric motility and emptying patterns. An acoustic sensor (contact microphone) will acquired these sounds while a computer analyzes and reports the presence or absence of changes consistent with a delayed gastric emptying diagnosis. We anticipate that the final product(s) will be both inexpensive and portable. This technology may lead to a substantial decrease in morbidity and health care costs associated with delayed gastric emptying. Phase 1 research will test feasibility in humans by documenting gastric sound patterns in normal subjects and those with delayed gastric emptying. If successful, the novel device would have major commercial potential with possible purchase by hospitals, medical and surgical group practices, plus specialty clinics serving diabetic, eating disorder, and gastroenterology patients. PROPOSED COMMERCIAL APPLICATIONS: This research is aimed at developed a novel diagnostic device with a potential large market. It is anticipated that these products will become standard equipment in hospitals, group medical practices and clinics serving patients with gastrointestinal complaints. The device will be of special use in following those at higher risk of delayed gastric emptying, such as those with diabetes, eating disorders, and renal failure. Preliminary 10 year sales and profit projections are 182 and 34 million dollars, respectively.